Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.

British journal of haematology - 1 Oct 2007

Toyama Kohtaro, Karasawa Masamitsu, Yamane Arito, Irisawa Hiroyuki, Yokohama Akihiko, Saitoh Takayuki, Handa Hiroshi, Matsushima Takafumi, Sawamura Morio, Miyawaki Shuichi, Murakami Hirokazu, Nojima Yoshihisa, Tsukamoto Norifumi

Abstract excerpt

There have been conflicting reports over the JAK2-V617F mutation status of platelets in chronic myeloproliferative diseases (CMPDs). The aim of this study was to analyse JAK2-V617F status, not only in granulocytes but also in platelets. The JAK2-V617F mutation was analysed in both granulocytes an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Platelets
Share to Granulocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Count

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Identifiers

PMID: 17854308
DOI: 10.1111/j.1365-2141.2007.06755.x

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17854308-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.PMID 17854308Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

Thrombocytosis and thrombosis.Semantic proximity Read ↗

Familial chronic myeloproliferative disorders: the state of the art.Semantic proximity Read ↗

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.Semantic proximity Read ↗

The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.Semantic proximity Read ↗

Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts.Semantic proximity Read ↗

<i>JAK2</i>V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation statusSemantic proximity Read ↗

Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause.Semantic proximity Read ↗

JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.Semantic proximity Read ↗

Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.